Liposome-induced pulmonary hypertension: Properties and mechanism of a complement-mediated pseudoallergic reaction

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 279, Issue 3 48-3, 2000, Pages

  Szebeni, Janos ^a   Baranyi, Lajos ^a   Savay, Sandor ^a   Bodo, Mihaly ^b   Morse, David S ^c   Basta, Milan ^d   Stahl, Gregory L ^c   Bünger, Rolf ^e   Alving, Carl R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b National Stroke Prevention Foundation   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Anaphylatoxin; Hemodynamics; Hemoglobin; Hypersensitivity reactions; IgM enriched intravenous immunoglobulin

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; CHOLESTEROL; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; CYCLOSPORIN A; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DISTEAROYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; DRUG; ENDOTOXIN; HEMOGLOBIN; IMMUNOGLOBULIN; INDOMETACIN; LIPOSOME; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BOLUS INJECTION; CARDIOPULMONARY INSUFFICIENCY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG RECHALLENGE; ENCAPSULATION; FLOW CYTOMETRY; HYPERSENSITIVITY REACTION; IMMEDIATE TYPE HYPERSENSITIVITY; INFUSION; LIPID COMPOSITION; LUNG CIRCULATION; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SWINE; VASOCONSTRICTION;

EID: 0033834805     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.2000.279.3.h1319     Document Type: Article

References (41)

1. Safety aspects of pegylated liposomal doxorubicin in patients with cancer
2. Liposomal drug formulations. Rationale for development and what we can expect for the future
3. Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes
4. Antibodies to cholesterol, cholesterol conjugates, and liposomes: Implications for atherosclerosis and autoimmunity
5. Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation
6. Actions of anaphylatoxin on circulation and respiration of the guinea pig
7. The role of complement and complement receptors in induction and regulation of immunity
8. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes
9. Characterization of porcine endothelial cell determinants recognized by human natural antibodies
10. The stability and structure of cholesterol-rich codispersions of cholesterol and phosphatidylcholine
11. Liposomal and lipid-based formulations of amphotericin B
12. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity
13. Ragweed allergy: Correlation between skin reactivity and in vitro complement activation
14. Safety assessment: Doxil (Doxorubicin HCl liposome injection) in refractory AIDS-related Kaposi's sarcoma
15. Interaction of anti-cholesterol antibodies with human lipoproteins
16. Left ventricular function during lethal and sublethal endotoxemia in swine
17. Atheroma cholesterol activates complement and aggregates granulocytes: Possible role in ischemic manifestations of atherosclerosis
18. Cholesterol and atheroma lipids activate complement and stimulate granulocytes
19. Activation of the alternative pathway of complement by microcrystalline cholesterol
20. Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten
21. Cardiopulmonary toxicity after liposomal amphotericin B infusion
22. The complement system
23. Effects of anaphylatoxins on circulation
24. Liposome-induced activation of the classical complement pathway does not require immunoglobulin
25. Influence of dose on liposome clearance: Critical role of blood proteins
26. Allergy and mechanism of hypersensitivity
27. Encapsulation of hemoglobin in liposomes
28. Allergic reactions and other rare side effects of liposomal amphotericin
29. Transient perturbation of endothelial cells induced by antibodies and complement
30. Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position
31. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil)
32. Antibodies to cholesterol
33. The interaction of liposomes with the complement system
34. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: A model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody
35. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study
36. Complement activation in vitro by the red blood cell substitute, liposome-encapsulated hemoglobin: Mechanism of activation and inhibition by soluble complement receptor type 1
37. Complement activation by liposome-encapsulated hemoglobin in vitro: The role of endotoxin contamination
38. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: Evidence for anti-lipid antibodies and alternative pathway activation
39. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies
40. Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs
41. Pilot-scale preparation of hemoglobin solutions